ClinicalTrials.gg
CompletedNCT03150875Updated Feb 28, 2023Results posted

A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC

A Phase 3 interventional study of IBI308 and Docetaxel in Non-small Cell Lung Cancer, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-02-28.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
290
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 46 studies testing sintilimab in Carcinoma, Non-Small-Cell Lung — 17 open to participants now, 22 under way, 4 of them phase 3. sintilimab · Carcinoma, Non-Small-Cell Lung.

Enrollment
5th of 46
290 · median 60
Started
2017
the only one that year
Phase 3
8 of 46
2 open now
Registered
1st of 46
by date
Lead sponsor
5 of 46
Innovent Biologics (Suzhou) Co. Ltd.

Among the 46 studies testing sintilimab in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by enrollment, is the only one that started in 2017, is one of 8 in phase 3, and was the 1st registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

17 of the 46 studies testing sintilimab in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

Where they have run

About sintilimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing sintilimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

Clinical trial results demonstrate that anti-PD-1 antibodies prolonged OS to approximately 9 months compared with 6 months in docetaxel group. Anti-PD-1 therapy in Chinese squamous NSCLC patients will be investigated in this clinical trial.

Additionally, the correlation between PD-L1 expression and the response to IBI308 treatment in Chinese squamous cell NSCLC patients as well as the role of irRECIST in immune checkpoint inhibitor treatment evaluation will also be assessed

03

Conditions studied

  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects with or cytologically confirmed squamous cell NSCLC
  2. Subjects with stage IIIB/stage IV or recurrent disease (not suitable for definitive concurrent chemoradiotherapy) (according to version 7 of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology) after failure of platinum-based therapy; Subjects who developed recurrent disease \<6 months after platinum-containing adjuvant, or definitive chemoradiation therapy also could also be eligible.
  3. At lease one according to (RECIST) 1.1
  4. Age ≥ 18 and ≤ 75
  5. performance status 0-1
  6. of at least 12 weeks
  7. Adequate organ and bone marrow function

    1. CBC: (ANC) ≥ 1.5 × 109 / L; count (PLT) ≥ 100 × 109 / L; content (HGB) ≥ 9.0 g / dL.
    2. Liver function: serum total (TBIL) ≤ 1.5 × normal upper limit (); (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; serum albumin ≥ 28 g / L.
    3. Renal function: serum creatinine (Cr) ≤ 1.5 × ULN, or rate (Ccr) ≥ 40 mL / min (calculated using Cockcroft / Gault equation) Female:CrCl= (140-Age) x Weight(kg) x 0.85 72 x Serum creatinine (mg/dL) Male:CrCl= (140-Age) x Weight(kg) x 1.00 72 x Serum creatinine (mg/dL)
  8. Subjects of must be willing to use adequate during the course of the study and through 6 months after the last dose of study treatment.
  9. Voluntarily signed written form, willing and able to comply with scheduled visits and other requirements of the study

Exclusion criteria

Exclusion Criteria:

  1. EGFR mutation and ALK rearrangement
  2. Mixed adeno-squamous carcinoma or other pathological type
  3. Prior therapy with ,anti-PD-L1,anti-CTLA4 antibody or docetaxel
  4. Have received following treatment:

    1. Received any agent within 4 weeks of the first dose of study treatment.
    2. Received any anti-tumor therapy (chemotherapy, targeted therapy, tumor immunotherapy or arterial embolization) within 3 weeks of the first dose of study treatment.
    3. Received radiotherapy within 4 weeks of the first dose of study treatment.
    4. Received systemic treatment with high-dose (> 10 mg daily prednisone equivalent) or other drugs within 4 weeks of first dose. Inhaled or topical steroids and adrenal replacement steroid are permitted in the absence of active disease.
    5. Received attenuated within 4 weeks of the first dose of study medication or plan to receive live vaccine during study period.
    6. Received major surgery (such as craniotomy, thoracotomy or laparotomy) within 4 weeks of the first dose of study drugs or open wound, ulcer or fracture.
  5. Unrecovered toxicity (grade >1, according to 4.03) due to prior anti-tumor therapy before the first dose of study treatment.
  6. Subjects with active, known or suspected autoimmune disease such as interstitial pneumonia, uveitis, Crohn's disease, autoimmune thyroiditis. Subjects with cured childhood asthma, type I diabetes mellitus and hypothyroidism only requiring hormone replacement, or skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment.
  7. Known history of allogeneic organ or allogeneic hemopoietic stem cell transplantation
  8. Known allergic or hypersensitive to docetaxel, any monoclonal antibody or any other components used in their preparation.
  9. Hemoptysis within 4 weeks of randomization (≥ 1/2 spoon per time).
  10. Received thoracic radiotherapy >30Gy within 6 months or palliative radiotherapy (brain or bone ) ≤30Gy within 7 days of randomization.
  11. Symptomatic central nervous system (CNS) metastasis and/or carcinomatous meningitis. Subjects should have stable disease more than 4 weeks from first dose of study treatment, with neurological symptoms returned to NCI CTCAE 4.03 grade 0 or 1, are permitted to enroll.
  12. Subjects with a history of interstitial lung disease
  13. Superior vena caval obstruction syndrome;
  14. Uncontrolled third space effusion, eg. ascites or pleural effusion.
  15. Uncontrolled concomitant disease, including but not limited to :

    1. Active or poorly controlled severe infection
    2. (HIV) infection (HIV antibody positive)
    3. Known acute or chronic active (HBV DNA positive) infection or acute or chronic active (HCV antibody positive and HCV RNA positive) infection
    4. Active tuberculosis
    5. Symptomatic congestive heart failure ( grade III-IV) or symptomatic, poorly controlled arrhythmia
    6. Uncontrolled hypertension (SBP ≥ 160mmHg or DBP ≥ 100mmHg)
    7. Prior arterial thromboembolism event, including myocardial infarction, unstable angina, stroke and , within 6 months of enrollment
    8. Concomitant disease needs anticoagulant therapy
    9. Uncontrolled hypercalcemia(Ca2+>1.5mmol/L or Ca >12mg/dl or corrected Serum Calcium >),or Symptomatic hypercalcemia during diphosphonate therapy
    10. Other primary , with the exception of: (radical Non-melanoma skin cancer or cured cervical in-situ carcinoma;)
  16. Subjects with other diseases or abnormal Lab test results which might increase the risk of enrollment and treatment or Interfere with the interpretation of study results could be excluded according to the judgments of investigator.
  17. Women who are pregnant or nursing
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
290 participants (actual)

Study arms

  • Experimental
    IBI308

    injection; dosage form: 10ml:100mg; frequency: 200mgQ3W; duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria

    Drug: IBI308

  • Active comparator
    docetaxel

    injection; dosage form: 1ml:40mg; Frequency: 75mg/m2 Q3W; duration: randomization to the date of the first documented tumor progression per RECIST v1.1 criteria

    Drug: Docetaxel

Interventions

  • DrugIBI308

    Anti-PD-1 therapy in Chinese squamous NSCLC patients will be investigated in this clinical trial.

  • As 2nd line treatment to subjects with squamous NSCLC

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Overall survival was defined as the time from randomization to death due to any cause.

    Time frame: Through database cutoff date of 31-July-2020 (up to approximately 35 months)

Secondary outcomes

  1. Progression-free Survival by Investigators' Assessment

    Progression-free survival (PFS) was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per Response Evaluation Criteria in Solid Tumours (RECIST 1.1), PD was defined as ≥20% increase in the sum of diameters of target lesions, or unequivocal progression of non-target lesion. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS as assessed by investigators per RECIST 1.1 was reported for each arm.

    Time frame: Through database cutoff date of 31-July-2020 (up to approximately 35 months)

  2. Overall Response Rate (ORR) Per RECIST v1.1 as Assessed by Investigators

    ORR was defined as the percentage of participants in the analysis population who had a confirmed Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1. The percentage of participants who experienced a CR or PR is presented.

    Time frame: Through database cutoff date of 31-July-2020 (up to approximately 35 months)

  3. Duration of Response (DOR) Per RECIST v1.1 as Assessed by Investigators

    For participants who demonstrated a CR (disappearance of all target lesions) or PR (≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of a CR or PR until PD or death. DOR for participants who had not progressed or died at the time of analysis was to be censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions or unequivoval progression of non-target lesion. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. The DOR per RECIST 1.1 for all participants who experienced a CR or PR is presented.

    Time frame: Through database cutoff date of 31-July-2020 (up to approximately 35 months)

  4. Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAE)

    TEAE is any AE that developed or worsened in severity compared to the baseline during the period from first dose of any study treatment up to 90 days after the last dose of any study treatment. Percentage of participants experiencing TEAE is calculated.

    Time frame: Through database cutoff date of 31-July-2020 (up to approximately 35 months)

07

Results

Posted Jun 23, 2021

Participant flow

Final analysis data cutoff date: 31-July-2020. Of the 290 randomized participants, 14 were ongoing. For efficacy analysis, full analysis set (FAS), Sintilimab (145) and Docetaxel (135), was used. 10 participants in the docetaxel arm who initiated immunotherapy before receving docetaxcel or disease progression were excluded from FAS.

Participant flow — Overall Study
MilestoneSintilimabDocetaxel
Started145145
Treated144130
Crossover to certain treatment00
Completed00
Not completed145145

Outcome measures

PrimaryOverall Survival

Overall survival was defined as the time from randomization to death due to any cause.

Time frame:
Through database cutoff date of 31-July-2020 (up to approximately 35 months)
Reported as:
Median · Months
Overall Survival
MonthsSintilimabDocetaxel
Overall Survival11.79 (10.28 to 15.27)8.25 (6.47 to 9.82)
SecondaryProgression-free Survival by Investigators' Assessment

Progression-free survival (PFS) was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per Response Evaluation Criteria in Solid Tumours (RECIST 1.1), PD was defined as ≥20% increase in the sum of diameters of target lesions, or unequivocal progression of non-target lesion. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS as assessed by investigators per RECIST 1.1 was reported for each arm.

Time frame:
Through database cutoff date of 31-July-2020 (up to approximately 35 months)
Reported as:
Median · Months
Progression-free Survival by Investigators' Assessment
MonthsSintilimabDocetaxel
Progression-free Survival by Investigators' Assessment4.3 (4.04 to 5.78)2.79 (1.91 to 3.19)
SecondaryOverall Response Rate (ORR) Per RECIST v1.1 as Assessed by Investigators

ORR was defined as the percentage of participants in the analysis population who had a confirmed Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters) per RECIST 1.1. The percentage of participants who experienced a CR or PR is presented.

Time frame:
Through database cutoff date of 31-July-2020 (up to approximately 35 months)
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR) Per RECIST v1.1 as Assessed by Investigators
Percentage of participantsSintilimabDocetaxel
Overall Response Rate (ORR) Per RECIST v1.1 as Assessed by Investigators25.5 (18.6 to 33.4)2.2 (0.5 to 6.4)
SecondaryDuration of Response (DOR) Per RECIST v1.1 as Assessed by Investigators

For participants who demonstrated a CR (disappearance of all target lesions) or PR (≥30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of a CR or PR until PD or death. DOR for participants who had not progressed or died at the time of analysis was to be censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions or unequivoval progression of non-target lesion. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions was also considered PD. The DOR per RECIST 1.1 for all participants who experienced a CR or PR is presented.

Time frame:
Through database cutoff date of 31-July-2020 (up to approximately 35 months)
Reported as:
Median · Months
Duration of Response (DOR) Per RECIST v1.1 as Assessed by Investigators
MonthsSintilimabDocetaxel
Duration of Response (DOR) Per RECIST v1.1 as Assessed by Investigators12.45 (4.86 to 25.33)4.14 (1.41 to 7.23)
SecondaryPercentage of Participants Experiencing Treatment-emergent Adverse Events (TEAE)

TEAE is any AE that developed or worsened in severity compared to the baseline during the period from first dose of any study treatment up to 90 days after the last dose of any study treatment. Percentage of participants experiencing TEAE is calculated.

Time frame:
Through database cutoff date of 31-July-2020 (up to approximately 35 months)
Reported as:
Number · Percentage of participants
Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAE)
Percentage of participantsSintilimabDocetaxel
Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAE)97.2096.20

Adverse events

Collected over Through database cutoff date of 31-July-2020 (up to approximately 35 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sintilimab108/144 (75%)56/144 (38.9%)132/144 (91.7%)
Docetaxel101/130 (77.7%)34/130 (26.2%)117/130 (90%)
Most frequent serious events
Showing 10 of 68
Most frequent serious events
EventSintilimabDocetaxel
PneumoniaInfections and infestations12/14414/130
White blood cell count decreasedInvestigations0/1445/130
PyrexiaGeneral disorders5/1443/130
Neutrophil count decreasedInvestigations0/1444/130
HaemoptysisRespiratory, thoracic and mediastinal disorders4/1442/130
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders4/1440/130
Immune-mediated pneumonitisRespiratory, thoracic and mediastinal disorders3/1440/130
PneumonitisRespiratory, thoracic and mediastinal disorders3/1440/130
Respiratory failureRespiratory, thoracic and mediastinal disorders3/1440/130
AstheniaGeneral disorders2/1442/130
Most frequent other events
Showing 10 of 49
Most frequent other events
EventSintilimabDocetaxel
AlopeciaSkin and subcutaneous tissue disorders0/14445/130
AnaemiaBlood and lymphatic system disorders48/14443/130
White blood cell count decreasedInvestigations6/14439/130
Neutrophil count decreasedInvestigations7/14438/130
AstheniaGeneral disorders25/14433/130
Decreased appetiteMetabolism and nutrition disorders34/14423/130
PyrexiaGeneral disorders31/14421/130
Weight decreasedInvestigations29/14414/130
CoughRespiratory, thoracic and mediastinal disorders29/14419/130
HypothyroidismEndocrine disorders27/1442/130

Baseline characteristics

Age, Continuous
Age, Continuous(Years)SintilimabDocetaxelTotal
Mean60.6 ± 8.1959.5 ± 8.4160.1 ± 8.30
Sex: Female, Male
Sex: Female, Male(Participants)SintilimabDocetaxelTotal
Female91322
Male136122258
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SintilimabDocetaxelTotal
Hispanic or Latino000
Not Hispanic or Latino145135280
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SintilimabDocetaxelTotal
American Indian or Alaska Native000
Asian145135280
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)SintilimabDocetaxelTotal
China145135280
08

Study locations

2 sites
  • The First Affiliated Hospital Zhejiang University
    Hangzhou, Zhejiang, China
  • Jiangsu Cancer Hospital
    Nanjing, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Feb 2023, 65 months.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 65 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2017
First posted
May 12, 2017
StartActual
Sep 1, 2017
Primary completionActual
Feb 22, 2023
CompletionActual
Feb 22, 2023
Results first posted
Jun 23, 2021
Last update
Feb 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03150875
Responsible party
Sponsor
First posted
May 12, 2017
Start date
Sep 1, 2017
Primary completion
Feb 22, 2023
Completion
Feb 22, 2023
Results posted
Jun 23, 2021
Last update
Feb 28, 2023

Study contacts

Yuankai Shi, Doctor
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sintilimab

Start the discussion